Brent D Rosenthal

Director Brent D Rosenthal buys 700 HKHC shares at $27.85, raising stake 40.0% to 2,450 shares

Brent D Rosenthal, a Director, purchased 700 shares at $27.85 on 2026-05-20, increasing his holdings from 1,750 shares to 2,450 shares. The current price of $27.85 sits 40.7% below the 52-week high of $47.00, and the stock is up 9.2% over the prior 30 days but down 0.5% over 90 days. His prior trades at HKHC show mixed timing outcomes: of 5 prior buys at this ticker, 3 of 5 were well-timed at the 90-day mark, though the most recent buy on 2026-03-18 showed a 30-day return of -22.3% and a 90-day return of -15.7%. The company's fundamentals include annual revenue growth of +27.4%, net income of $72,532,000.00, and a P/E of 9.47, indicating profitable operations with relatively attractive valuation metrics.

Director Rosenthal buys 750 HKHC shares at $33.05; 75% increase in holdings amid cluster buy pattern

Director Brent D Rosenthal purchased 750 shares of Horizon Kinetics Holding Corp on 2026-03-18 at $33.05, expanding his holdings from 1,000 to 1,750 shares (+75.0%). This transaction occurs within a cluster pattern: 2 other insiders bought within the past 14 days, suggesting coordinated confidence at current valuations. Rosenthal's prior trade history at HKHC shows mixed but notably strong 90-day returns: 3 of 4 prior buys were well-timed, with his November 2025 buy returning +17.3% over 90 days. However, his cross-ticker track record shows an average 90-day return of -3.2% across 8 buys, with a 71.43% win rate, indicating this purchase sits above his typical historical baseline. The stock has rebounded 42.6% over 90 days and trades at a P/E of 79.07 against 27.4% revenue growth and $7.2M net income last quarter, reflecting elevated valuation multiples relative to fundamentals.

Director Rosenthal bought 4,000 PBI shares at $10.22; holdings +80% to 9.0K shares; P/E 3.63, annual revenue down 6.6%.

Rosenthal Brent D, a director, purchased 4,000 shares at $10.22 on 2026-03-13, increasing his holdings by 80.0% from 5,000 shares to 9,000 shares. The transaction occurs at a price significantly below the 52-week high of $12.79 (-18.9%), and the company trades at a historically low P/E of 3.63 amid declining fundamentals: annual revenue contracted 6.6% year-over-year, though the latest quarter delivered $459.7M in revenue and $52.0M in net income. His prior two buys at this ticker (both on 2025-11-25) both achieved positive 90-day returns of +3.8%, suggesting some timing capability at this specific stock, though a 2025-09-03 buy returned -20.6% at the 90-day mark. The current share price of $10.37 is only $0.15 above the transaction price, leaving minimal near-term appreciation, and his cross-ticker buy history shows an average 90-day return of -3.2% despite a 71.43% win rate. This purchase warrants monitoring to determine whether the depressed valuation and modest recent precedent of well-timed buys at PBI will extend to this transaction.

Director Rosenthal buys 300 HKHC shares at $27.28; holds 1,000 post-transaction amid cluster buying pattern.

Rosenthal Brent D, a Director, purchased 300 shares at $27.28 on 2025-11-25, increasing his holdings by 42.9% from 700 to 1,000 shares. The timing coincides with a broader cluster pattern: 2 other insiders also bought within the past 14 days. His prior transaction history at HKHC shows a 100% win rate on measurable 90-day outcomes (2 of 2 prior buys at this ticker yielded positive 90-day returns of +2.5%), though the current price of $27.23 is -42.1% from the 52-week high of $47.00 and down 28.3% over 90 days. The company's fundamentals show strong profitability (net income $7.2M on revenue $17.9M) and an exceptional P/E of 5.32, though recent stock performance has deteriorated sharply.

Director Rosenthal bought 2,000 shares at $10.00 on 2025-11-25, bringing holdings to 5.0K; stock now at $9.90 (-22.6% from 52-week high).

Director Brent D Rosenthal purchased 2,000 shares in 2 separate open-market transactions totaling $20,002.50 at $10.00 per share on 2025-11-25, increasing his holdings from 3,000 shares to 5,000 shares. The stock is currently trading at $9.90, down 22.6% from its 52-week high and down 15.9% over the past 30 days, suggesting the purchase occurred amid recent weakness. The company's fundamentals are strained: annual revenue growth is -38.0%, and the company was unprofitable over its most recent full fiscal year, with the latest quarter showing net income of $52.0M against revenue of $459.7M. His prior purchase at PBI on 2025-09-03 showed a -7.1% 30-day return, and across his 5 prior cross-ticker open-market buys his average 90-day return has been +2.5%, though his same-ticker track record remains limited.

Director Rosenthal buys 3,000 shares of PBI at $11.97 for $35,909.70, first purchase ever

Brent D Rosenthal, a Director, made his first-ever open-market purchase of Pitney Bowes, acquiring 3,000 shares at $11.97 on 2025-09-03 for a total of $35,909.70. The transaction occurred within the company's 52-week price range of $6.44–$12.79, and at 4.0% below the 52-week high. While his cross-ticker track record shows 3 prior buys with a 100.00% 90-day win rate and average 90-day return of +2.5%, PBI itself has shown material weakness: annual revenue declined -38.0% and the company posted negative full-year net income. The stock's recent momentum (+7.7% over 30 days, +16.6% over 90 days) has partially recovered from depressed levels, but the company's deteriorating profitability and revenue trajectory present structural headwinds that distinguish this entry from his prior successful accumulations elsewhere.

Director Rosenthal buys 300 HKHC shares at $38.00; stock now $37.85, down 28.6% from 52-week high; cluster pattern emerges with 2 other insiders buying within 14 days.

Director Brent D Rosenthal purchased 300 shares at $38.00, increasing his holdings by 75.0% from 400 to 700 shares, in a transaction that occurred as the stock trades 28.6% below its 52-week high of $53.00. This buy is part of a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or independent conviction at current levels. Rosenthal's prior two purchases at HKHC (on 2024-11-14 and 2024-11-19) both generated positive 90-day returns of +2.5%, establishing a track record of well-timed buys at this ticker, though the stock has since declined 4.2% over the past 30 days. The company's financials present a mixed picture: revenue grew 1580.3% annually and the market cap stands at $705.3M, but the latest quarter showed net income of $-10.5M on revenue of $19.8M, indicating ongoing profitability challenges that warrant investor scrutiny of the company's path to sustainable earnings.

Rosenthal bought 100 HKHC shares at $37.06; 5 insiders bought in past 14 days amid -79.5% revenue decline and -$38.2M net loss.

Director Rosenthal Brent D purchased 100 shares at $37.06, increasing his holdings from 300 to 400 shares (+33.3% vs pre-transaction holdings). This transaction is part of a cluster pattern with 5 other insiders also buying within the past 14 days. However, the company's fundamentals are severely deteriorated: annual revenue growth shows -79.5%, the latest quarter posted net income of -$38.2M against revenue of $15.4M, and the stock trades at a 32.1% discount from its 52-week high of $53.00. The stock is near its 52-week low of $19.52 range, yet insiders are accumulating. The synchronized buying across multiple insiders during a period of sharp financial contraction and depressed valuation warrants investigation into whether this reflects conviction in a turnaround or represents an attempt to support a deteriorating stock price.

Director Rosenthal buys 300 HKHC shares at $38.06; 3 other insiders also bought within 14 days amid -79.5% YoY revenue decline.

Brent D. Rosenthal, a Director, purchased 300 shares of Horizon Kinetics Holding Corp at $38.06 on November 14, 2024, establishing a new position after holding zero shares. This purchase is part of a cluster buy pattern with 3 other insiders acquiring shares within the same 14-day window. The timing raises questions given the company's severe financial deterioration: annual revenue has declined 79.5% year-over-year (from $15.4M latest quarter), net income stands at negative $38.2M, and the stock has fallen 26.9% from its 52-week high despite a recent 30-day bounce of 54.3%. Coordinated insider purchases during periods of sharp financial decline and pronounced downward trend warrant close examination of management's strategic outlook and whether insiders possess non-public information justifying accumulation at distressed valuations.